AiCure

Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Edward Lanphier elected chairman of the Alliance for Regenerative Medicine

Thursday, November 13, 2014 02:15 PM

Sangamo BioSciences has announced that Edward Lanphier, the company's president and CEO, has been elected as the next chairman of the Alliance for Regenerative Medicine (ARM). Wash. D.C.-based ARM is an international organization that represents and supports industry, clinical institutions, patient advocates and other stakeholders in the development of safe and effective gene and cell therapies. Lanphier succeeds Geoff MacKay, president and CEO of Organogenesis, who will complete his two-year term as chairman on Dec. 31.

More... »


inVentiv Health names Jeffrey Wilks president of advertising

Thursday, November 13, 2014 02:10 PM

inVentiv Health, a life science knowledge and services company for the new healthcare environment, has appointed of Jeffrey Wilks as president of its advertising businesses. Wilks will report to Mike Griffith, executive vice president, inVentiv Health and president, inVentiv Commercial.

More... »


Greenphire Joins the Deloitte 2014 Technology Fast 500

Thursday, November 13, 2014 01:49 PM

Greenphire, a provider of payment technology for the clinical trials industry, has won a place in Deloitte's 2014 Technology Fast 500. Ranking 48th in the annual list of the fastest growing technology companies in the U.S, Greenphire secured its place as a result of an exceptional 2782% growth over the past four years.

More... »

Bracket releases Rater Station 3.5

Thursday, November 13, 2014 08:00 AM

Bracket, a global specialty service provider, has released Rater Station 3.5, a core technology platform. Rater Station 3.5 offers the advantages of a single system for management of clinical trial data collection and advanced Endpoint Reliability solutions.

More... »

Dendreon files for bankruptcy protection

Wednesday, November 12, 2014 03:30 PM

Dendreon, a Seattle-based biotechnology company, and its U.S. subsidiaries filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on Nov. 10.

More... »

Clinerion launches real-time patient recruitment system to boost trial recruitment

Wednesday, November 12, 2014 03:27 PM

Clinerion, a Swiss-based software and services company, has launched its Patient Recruitment System (PRS). Clinerion’s PRS radically boosts recruitment for clinical trials, identifying 10 to 30 times more suitable candidates than those found through a classical manual screening approach, and in a matter of minutes rather than the weeks or months typically needed.

More... »

Qiagen inks ninth master collaboration agreement for companion diagnostics

Wednesday, November 12, 2014 03:26 PM

Qiagen, a Netherlands-based holding company, has entered into a master collaboration agreement with the Swiss pharmaceutical company Novartis to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline.

More... »

Consort Medical acquires Aesica

Wednesday, November 12, 2014 03:26 PM

Consort has completed its acquisition of Aesica Holdco. The acquisition is directly in line with Consort's articulated strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain.

More... »

Coté Orphan launches CRO to simplify orphan drug developement process

Wednesday, November 12, 2014 03:22 PM

Coté Orphan, a regulatory affairs advisory firm based in Silver Spring, Md., has added a new line of service for its clients by providing CRO services that will help organizations navigate the clinical trials process through the lens of regulatory affairs. With the addition of the CRO services, Coté Orphan provides companies a complete and robust solution to those developing or seeking to develop orphan drugs.

More... »

Report: Big biopharma would rather ‘make than buy’

Wednesday, November 12, 2014 03:21 PM

Global and generic biopharma companies will continue to prefer in-house manufacturing to outsourcing for the most strategic elements of their businesses, according to a report by PharmSource Information Services, a Virginia-based provider of market intelligence for the global contract biopharma industry.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs